Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cognition Therapeutics Inc CGTX

Healthcare Biotechnology
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812... see more

Recent & Breaking News (NDAQ:CGTX)

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

GlobeNewswire June 3, 2025

Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

GlobeNewswire May 28, 2025

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

GlobeNewswire May 9, 2025

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

GlobeNewswire May 8, 2025

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

GlobeNewswire May 7, 2025

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

GlobeNewswire April 1, 2025

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

GlobeNewswire March 25, 2025

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

GlobeNewswire March 20, 2025

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

GlobeNewswire March 13, 2025

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

GlobeNewswire March 12, 2025

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

GlobeNewswire March 10, 2025

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

GlobeNewswire February 27, 2025

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

GlobeNewswire February 26, 2025

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

GlobeNewswire February 25, 2025

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812)

GlobeNewswire February 20, 2025

Cognition's Positive Phase 2 'SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

GlobeNewswire January 30, 2025

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

GlobeNewswire January 8, 2025

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

GlobeNewswire December 18, 2024

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

GlobeNewswire November 26, 2024

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

GlobeNewswire November 25, 2024